Breast Cancer Research and Treatment

, Volume 133, Issue 2, pp 413–416 | Cite as

Thinking beyond the tumor to better understand chronic symptoms in breast cancer survivors

Invited Commentary


Breast Cancer Chronic Pain Fibromyalgia Breast Cancer Survivor Duloxetine 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.



NLH is the Damon Runyon-Lilly Clinical Investigator supported (in part) by the Damon Runyon Cancer Research Foundation (CI-53-10).


NLH receives research funding from Eli Lilly, AstraZeneca, and Sanofi Aventis. DJC receives research funding from Forest Laboratories and Merck and is a consultant for Cypress Biosciences, Eli Lilly, Forest Laboratories, Jazz Pharmaceuticals, Merck, Pierre Fabre Pharmaceuticals USA, Pfizer, and UCB.


  1. 1.
    American Cancer Society: Breast Cancer Facts & Figures 2009–2010.–figures-2009-2010. Accessed 25 Aug 2011
  2. 2.
    Bower JE (2008) Behavioral symptoms in patients with breast cancer and survivors. J Clin Oncol 26:768–777PubMedCrossRefGoogle Scholar
  3. 3.
    Giesecke T, Gracely RH, Grant MA, Nachemson A, Petzke F, Williams DA, Clauw DJ (2004) Evidence of augmented central pain processing in idiopathic chronic low back pain. Arthritis Rheum 50:613–623PubMedCrossRefGoogle Scholar
  4. 4.
    Gracely RH, Petzke F, Wolf JM, Clauw DJ (2002) Functional magnetic resonance imaging evidence of augmented pain processing in fibromyalgia. Arthritis Rheum 46:1333–1343PubMedCrossRefGoogle Scholar
  5. 5.
    Clauw D (2003) The health consequences of the first gulf war. Br Med J 327:1357–1358CrossRefGoogle Scholar
  6. 6.
    Clauw DJ, Engel CC Jr, Aronowitz R, Jones E, Kipen HM, Kroenke K, Ratzan S, Sharpe M, Wessely S (2003) Unexplained symptoms after terrorism and war: an expert consensus statement. J Occup Environ Med 45:1040–1048PubMedCrossRefGoogle Scholar
  7. 7.
    Hassett AL, Clauw DJ (2010) The role of stress in rheumatic diseases. Arthritis Res Ther 12:123PubMedCrossRefGoogle Scholar
  8. 8.
    Mogil JS, Yu L, Basbaum AI (2000) Pain genes?: natural variation and transgenic mutants. Annu Rev Neurosci 23:777–811PubMedCrossRefGoogle Scholar
  9. 9.
    Diatchenko L, Slade GD, Nackley AG et al (2005) Genetic basis for individual variations in pain perception and the development of a chronic pain condition. Hum Mol Genet 14:135–143PubMedCrossRefGoogle Scholar
  10. 10.
    Zubieta JK, Heitzeg MM, Smith YR, Bueller JA, Xu K, Xu Y, Koeppe RA, Stohler CS, Goldman D (2003) COMT Val158Met genotype affects mu-opioid neurotransmitter responses to a pain stressor. Science 299:1240–1243PubMedCrossRefGoogle Scholar
  11. 11.
    Costigan M, Belfer I, Griffin RS et al (2010) Multiple chronic pain states are associated with a common amino acid-changing allele in KCNS1. Brain 133:2519–2527PubMedCrossRefGoogle Scholar
  12. 12.
    Tegeder I, Costigan M, Griffin RS et al (2006) GTP cyclohydrolase and tetrahydrobiopterin regulate pain sensitivity and persistence. Nat Med 12:1269–1277PubMedCrossRefGoogle Scholar
  13. 13.
    Valdes AM, De Wilde G, Doherty SA et al (2011) The Ile585Val TRPV1 variant is involved in risk of painful knee osteoarthritis. Ann Rheum Dis 70:1556–1561PubMedCrossRefGoogle Scholar
  14. 14.
    Galvan A, Fladvad T, Skorpen F, Gao X, Klepstad P, Kaasa S, Dragani TA (2011) Genetic clustering of European cancer patients indicates that opioid-mediated pain relief is independent of ancestry. Pharmacogenomics J. doi:10.1038/tpj.2011.27Google Scholar
  15. 15.
    Droney J, Riley J, Ross JR (2011) Evolving knowledge of opioid genetics in cancer pain. Clin Oncol 23:418–428CrossRefGoogle Scholar
  16. 16.
    Williams DA, Clauw DJ (2009) Understanding fibromyalgia: lessons from the broader pain research community. J Pain 10:777–791PubMedCrossRefGoogle Scholar
  17. 17.
    Fernandez-de-Las-Penas C, Fernandez-Lao C, Cantarero-Villanueva I, Ambite-Quesada S, Rivas-Martinez I, del Moral-Avila R, Arroyo-Morales M (2011) Catechol-o-methyltransferase genotype (Val158Mmet) modulates cancer-related fatigue and pain sensitivity in breast cancer survivors. Breast Cancer Res Treat (in press)Google Scholar
  18. 18.
    van Meurs JB, Uitterlinden AG, Stolk L, Kerkhof HJ, Hofman A, Pols HA, Bierma-Zeinstra SM (2009) A functional polymorphism in the catechol-o-methyltransferase gene is associated with osteoarthritis-related pain. Arthritis Rheum 60:628–629PubMedCrossRefGoogle Scholar
  19. 19.
    McLean SA, Diatchenko L, Lee YM et al (2011) Catechol o-methyltransferase haplotype predicts immediate musculoskeletal neck pain and psychological symptoms after motor vehicle collision. J Pain 12:101–107PubMedCrossRefGoogle Scholar
  20. 20.
    Yarnitsky D, Crispel Y, Eisenberg E, Granovsky Y, Ben-Nun A, Sprecher E, Best LA, Granot M (2008) Prediction of chronic post-operative pain: pre-operative DNIC testing identifies patients at risk. Pain 138:22–28PubMedCrossRefGoogle Scholar
  21. 21.
    Dodd MJ, Cho MH, Cooper BA, Miaskowski C (2010) The effect of symptom clusters on functional status and quality of life in women with breast cancer. Eur J Oncol Nurs 14:101–110PubMedCrossRefGoogle Scholar
  22. 22.
    Aktas A, Walsh D, Rybicki L (2010) Symptom clusters: myth or reality? Palliat Med 24:373–385PubMedCrossRefGoogle Scholar
  23. 23.
    Arnold LM, Rosen A, Pritchett YL, D’Souza DN, Goldstein DJ, Iyengar S, Wernicke JF (2005) A randomized, double-blind, placebo-controlled trial of duloxetine in the treatment of women with fibromyalgia with or without major depressive disorder. Pain 119:5–15PubMedCrossRefGoogle Scholar
  24. 24.
    Chappell AS, Ossanna MJ, Liu-Seifert H, Iyengar S, Skljarevski V, Li LC, Bennett RM, Collins H (2009) Duloxetine, a centrally acting analgesic, in the treatment of patients with osteoarthritis knee pain: a 13-week, randomized, placebo-controlled trial. Pain 146:253–260PubMedCrossRefGoogle Scholar
  25. 25.
    Mease PJ, Clauw DJ, Gendreau RM, Rao SG, Kranzler J, Chen W, Palmer RH (2009) The efficacy and safety of milnacipran for treatment of fibromyalgia. A randomized, double-blind, placebo-controlled trial. J Rheumatol 36:398–409PubMedCrossRefGoogle Scholar
  26. 26.
    Thieme K, Gracely RH (2009) Are psychological treatments effective for fibromyalgia pain? Curr Rheumatol Rep 11:443–450PubMedCrossRefGoogle Scholar
  27. 27.
    Henry NL, Giles JT, Stearns V (2008) Aromatase inhibitor-associated musculoskeletal symptoms: etiology and strategies for management. Oncology (Williston Park) 22:1401–1408Google Scholar
  28. 28.
    Crew KD, Capodice JL, Greenlee H, Brafman L, Fuentes D, Awad D, Yann Tsai W, Hershman DL (2010) Randomized, blinded, sham-controlled trial of acupuncture for the management of aromatase inhibitor-associated joint symptoms in women with early-stage breast cancer. J Clin Oncol 28:1154–1160PubMedCrossRefGoogle Scholar
  29. 29.
    Henry NL, Banerjee M, Wicha M, Van Poznak C, Smerage JB, Schott AF, Griggs JJ, Hayes DF (2011) Pilot study of duloxetine for treatment of aromatase inhibitor-associated musculoskeletal symptoms. Cancer. doi:10.1002/cncr.26230Google Scholar

Copyright information

© Springer Science+Business Media, LLC. 2011

Authors and Affiliations

  1. 1.Division of Hematology/Oncology, Department of Internal MedicineUniversity of Michigan Medical SchoolAnn ArborUSA
  2. 2.Department of AnesthesiologyUniversity of Michigan Medical SchoolAnn ArborUSA

Personalised recommendations